Phylogeny  
• Classified in the group G branch of the human kinome and designated a class 1 pseudokinase because the kinase-like domain lacks the canonical VAIK, HRD and DFG catalytic motifs (kerr2013nuclearreceptorbindingprotein pages 2-4, murphy2014arobustmethodology pages 7-9).  
• Forms a distinct NRBP1/NRBP2 clade within the “other/atypical” sector of the kinome (yang2024targetingtheparalog pages 44-48).  
• Orthologous conservation: Homo sapiens vs Mus musculus 98.3 % identity, Caenorhabditis elegans 60.7 %, Drosophila melanogaster 53.8 % (kerr2013nuclearreceptorbindingprotein pages 2-4).  

Reaction Catalyzed  
NRBP1 does not catalyze the canonical protein-serine/threonine kinase reaction (ATP + protein-OH → ADP + protein-O-phosphate); no nucleotide binding or phosphoryl-transfer activity is detected (murphy2014arobustmethodology pages 7-9).  

Cofactor Requirements  
No Mg²⁺, Mn²⁺ or other divalent cation requirement has been observed, consistent with absent nucleotide binding (murphy2014arobustmethodology pages 7-9).  

Substrate Specificity  
A phosphorylation consensus motif is undefined because NRBP1 is catalytically inactive (murphy2014arobustmethodology pages 7-9).  

Structure  
• Domain organisation: SH2-interaction segment (aa 1-70), nuclear export signal (aa 121-129), pseudokinase domain (aa 73-327), nuclear localisation signal (aa 163-181), BC-box for Elongin B/C binding (aa 332-341), LisH/Cullin interaction region, MLF1-binding segment (aa 406-479), two LXXLL nuclear-receptor motifs (aa 462-466; 507-511) and a TSC22-binding module (kerr2013nuclearreceptorbindingprotein pages 1-2, yang2023thepseudokinasenrbp1 pages 2-3).  
• AlphaFold models preserve the bilobal protein-kinase scaffold yet confirm degradation of the catalytic lysine in the β3-strand, the catalytic HRD aspartate and the DFG motif, eliminating the regulatory spine and C-helix salt bridge (yang2023thepseudokinasenrbp1 pages 14-14).  
• Thermal-shift screens show no binding to ATP, ADP or divalent cations, corroborating structural incompetence for catalysis (murphy2014arobustmethodology pages 7-9).  
• The BC-box forms an exposed surface for CRL5 assembly, a feature absent from canonical active kinases (kerr2013nuclearreceptorbindingprotein pages 2-4).  

Regulation  
• Phosphorylation: multiple sites identified by phospho-proteomics; specific residues and responsible kinases are not yet mapped (yang2023thepseudokinasenrbp1 pages 14-14).  
• Ubiquitination: the BC-box recruits Elongin B/C and CUL5, positioning NRBP1 as the substrate-recognition module of a CRL5 E3 ligase; NRBP1 itself and bound substrates are ubiquitinated (kerr2013nuclearreceptorbindingprotein pages 2-4). Additional CRL2 and CRL4A assemblies promote NRBP1 turnover (maganaavila2024nrbp1andtsc22d pages 16-17).  
• Osmotic stress: binding to WNK kinases modulates CRL5 association during osmotic adaptation (amnekar2024nrbp1pseudokinasebinds pages 25-27).  
• Subcellular distribution is regulated by intrinsic NES and NLS signals allowing cytoplasm–nucleus shuttling (kerr2013nuclearreceptorbindingprotein pages 1-2).  

Function  
• Expression is ubiquitous across mammalian tissues (kerr2013nuclearreceptorbindingprotein pages 1-2).  
• Development: Nrbp1-/- embryos die at E7.5, indicating an essential embryonic function (kerr2013nuclearreceptorbindingprotein pages 4-5).  
• Intestine: conditional knockout causes crypt elongation, elevated progenitor proliferation and increased expression of Wnt-responsive genes (kerr2013nuclearreceptorbindingprotein pages 4-5).  
• Ubiquitination adaptor: serves as the substrate-selector in CRL5 complexes (kerr2013nuclearreceptorbindingprotein pages 2-4).  
• Trafficking: binds activated Rac3 to influence ER-to-Golgi transport (kerr2013nuclearreceptorbindingprotein pages 2-4).  
• Oncogenic signaling: scaffolds P-Rex1 with Rac1/Cdc42, enhancing GTPase activation, ROS production, migration, invasion and metastasis in triple-negative breast cancer (yang2023thepseudokinasenrbp1 pages 7-8).  
• Osmoregulation: associates with WNK kinases to modulate distal convoluted tubule signaling (amnekar2024nrbp1pseudokinasebinds pages 25-27, maganaavila2024nrbp1andtsc22d pages 16-17).  
• Viral replication: interaction with dengue virus NS3 protein alters intracellular membrane architecture (yang2023thepseudokinasenrbp1 pages 14-14).  
• Transcriptional repression: binds JAB1, inhibiting AP-1 activity (kerr2013nuclearreceptorbindingprotein pages 5-5).  

Inhibitors  
No small-molecule inhibitors have been reported.  

Other Comments  
• Tumour biology is context-dependent: NRBP1 down-regulation correlates with poor survival in lung and colorectal adenocarcinomas and cooperates genetically with oncogenic KRAS (kerr2013nuclearreceptorbindingprotein pages 4-5). Conversely, elevated NRBP1 drives proliferation and invasion in triple-negative breast, bladder and prostate cancers (yang2023thepseudokinasenrbp1 pages 1-2, yang2023thepseudokinasenrbp1 pages 14-14).  
• NRBP1 promotes PI3K/AKT-dependent malignant phenotypes in glioblastoma (zhang2024nrbp1promotesmalignant pages 16-16).  
• Functional interplay with the paralogue NRBP2 governs LINE-1 retrotransposition, providing a mechanistic basis for tissue-specific phenotypes (yang2024targetingtheparalog pages 44-48).

References

1. (amnekar2024nrbp1pseudokinasebinds pages 25-27): Ramchandra V Amnekar, Toby Dite, Pawel Lis, Sebastian Bell, Fiona Brown, Clare Johnson, Stuart Wilkinson, Samantha Raggett, Mark Dorward, Mel Wightman, Thomas Macartney, Renata F Soares, Frederic Lamoliatte, and Dario R Alessi. Nrbp1 pseudokinase binds to and activates the wnk pathway in response to osmotic stress. bioRxiv, Dec 2024. URL: https://doi.org/10.1101/2024.12.12.628181, doi:10.1101/2024.12.12.628181. This article has 2 citations.

2. (kerr2013nuclearreceptorbindingprotein pages 1-2): Jason S. Kerr and Catherine H. Wilson. Nuclear receptor-binding protein 1: a novel tumour suppressor and pseudokinase. Biochemical Society transactions, 41 4:1055-60, Aug 2013. URL: https://doi.org/10.1042/bst20130069, doi:10.1042/bst20130069. This article has 31 citations and is from a peer-reviewed journal.

3. (kerr2013nuclearreceptorbindingprotein pages 5-5): Jason S. Kerr and Catherine H. Wilson. Nuclear receptor-binding protein 1: a novel tumour suppressor and pseudokinase. Biochemical Society transactions, 41 4:1055-60, Aug 2013. URL: https://doi.org/10.1042/bst20130069, doi:10.1042/bst20130069. This article has 31 citations and is from a peer-reviewed journal.

4. (yang2023thepseudokinasenrbp1 pages 1-2): Xue Yang, Miguel I Cruz, Elizabeth V. Nguyen, Cheng Huang, R. Schittenhelm, Jennii Luu, K. Cowley, Sung-young Shin, Leann Nguyen, Terry C. C. Lim Kam Sian, Kimberley C Clark, K. Simpson, Xiuquan Ma, and R. Daly. The pseudokinase nrbp1 activates rac1/cdc42 via p-rex1 to drive oncogenic signalling in triple-negative breast cancer. Oncogene, 42:833-847, Jan 2023. URL: https://doi.org/10.1038/s41388-023-02594-w, doi:10.1038/s41388-023-02594-w. This article has 10 citations and is from a domain leading peer-reviewed journal.

5. (yang2023thepseudokinasenrbp1 pages 14-14): Xue Yang, Miguel I Cruz, Elizabeth V. Nguyen, Cheng Huang, R. Schittenhelm, Jennii Luu, K. Cowley, Sung-young Shin, Leann Nguyen, Terry C. C. Lim Kam Sian, Kimberley C Clark, K. Simpson, Xiuquan Ma, and R. Daly. The pseudokinase nrbp1 activates rac1/cdc42 via p-rex1 to drive oncogenic signalling in triple-negative breast cancer. Oncogene, 42:833-847, Jan 2023. URL: https://doi.org/10.1038/s41388-023-02594-w, doi:10.1038/s41388-023-02594-w. This article has 10 citations and is from a domain leading peer-reviewed journal.

6. (yang2024targetingtheparalog pages 44-48): Wei Yang, Shaobo Cong, Jennifer Schwarz, Thilo Schulze, Sara Ullrich, Kristina Falkenstein, Denis Ott, Pia Eixmann, Angelica Trentino, Antje Thien, Thierry Heidmann, Ekkehard Schulze, Bettina Warscheid, Ralf Baumeister, and Wenjing Qi. Targeting the paralog protein for degradation accounts for the opposite roles of nrbp1 and nrbp2 in regulating line1 retrotransposition. BioRxiv, Jun 2024. URL: https://doi.org/10.1101/2024.06.14.598964, doi:10.1101/2024.06.14.598964. This article has 0 citations.

7. (kerr2013nuclearreceptorbindingprotein pages 2-4): Jason S. Kerr and Catherine H. Wilson. Nuclear receptor-binding protein 1: a novel tumour suppressor and pseudokinase. Biochemical Society transactions, 41 4:1055-60, Aug 2013. URL: https://doi.org/10.1042/bst20130069, doi:10.1042/bst20130069. This article has 31 citations and is from a peer-reviewed journal.

8. (kerr2013nuclearreceptorbindingprotein pages 4-5): Jason S. Kerr and Catherine H. Wilson. Nuclear receptor-binding protein 1: a novel tumour suppressor and pseudokinase. Biochemical Society transactions, 41 4:1055-60, Aug 2013. URL: https://doi.org/10.1042/bst20130069, doi:10.1042/bst20130069. This article has 31 citations and is from a peer-reviewed journal.

9. (yang2023thepseudokinasenrbp1 pages 7-8): Xue Yang, Miguel I Cruz, Elizabeth V. Nguyen, Cheng Huang, R. Schittenhelm, Jennii Luu, K. Cowley, Sung-young Shin, Leann Nguyen, Terry C. C. Lim Kam Sian, Kimberley C Clark, K. Simpson, Xiuquan Ma, and R. Daly. The pseudokinase nrbp1 activates rac1/cdc42 via p-rex1 to drive oncogenic signalling in triple-negative breast cancer. Oncogene, 42:833-847, Jan 2023. URL: https://doi.org/10.1038/s41388-023-02594-w, doi:10.1038/s41388-023-02594-w. This article has 10 citations and is from a domain leading peer-reviewed journal.

10. (zhang2024nrbp1promotesmalignant pages 16-16): Anli Zhang, Shichao Peng, Sibai Sun, Shan Ye, Ye Zhao, and Qiang Wu. <scp>nrbp1</scp> promotes malignant phenotypes of glioblastoma by regulating <scp>pi3k</scp>/akt activation. Cancer Medicine, Aug 2024. URL: https://doi.org/10.1002/cam4.70100, doi:10.1002/cam4.70100. This article has 3 citations and is from a peer-reviewed journal.

11. (maganaavila2024nrbp1andtsc22d pages 16-17): Germán Magaña-Ávila, Héctor Carbajal-Contreras, Ramchandra Amnekar, Toby Dite, Michelle Téllez-Sutterlin, Kevin García-Ávila, Brenda Marquina-Castillo, Alejandro Lopez-Saavedra, N. Vázquez, Eréndira Rojas-Ortega, Eric Delpire, David H. Ellison, D. Alessi, Gerardo Gamba, and María Castañeda-Bueno. Nrbp1 and tsc22d proteins impact distal convoluted tubule physiology through modulation of the wnk pathway. bioRxiv, Dec 2024. URL: https://doi.org/10.1101/2024.12.12.628222, doi:10.1101/2024.12.12.628222. This article has 2 citations.

12. (murphy2014arobustmethodology pages 7-9): James M. Murphy, Qingwei Zhang, Samuel N. Young, Michael L. Reese, Fiona P. Bailey, Patrick A. Eyers, Daniela Ungureanu, Henrik Hammaren, Olli Silvennoinen, Leila N. Varghese, Kelan Chen, Anne Tripaydonis, Natalia Jura, Koichi Fukuda, Jun Qin, Zachary Nimchuk, Mary Beth Mudgett, Sabine Elowe, Christine L. Gee, Ling Liu, Roger J. Daly, Gerard Manning, Jeffrey J. Babon, and Isabelle S. Lucet. A robust methodology to subclassify pseudokinases based on their nucleotide-binding properties. The Biochemical journal, 457 2:323-34, Jan 2014. URL: https://doi.org/10.1042/bj20131174, doi:10.1042/bj20131174. This article has 295 citations.

13. (yang2023thepseudokinasenrbp1 pages 2-3): Xue Yang, Miguel I Cruz, Elizabeth V. Nguyen, Cheng Huang, R. Schittenhelm, Jennii Luu, K. Cowley, Sung-young Shin, Leann Nguyen, Terry C. C. Lim Kam Sian, Kimberley C Clark, K. Simpson, Xiuquan Ma, and R. Daly. The pseudokinase nrbp1 activates rac1/cdc42 via p-rex1 to drive oncogenic signalling in triple-negative breast cancer. Oncogene, 42:833-847, Jan 2023. URL: https://doi.org/10.1038/s41388-023-02594-w, doi:10.1038/s41388-023-02594-w. This article has 10 citations and is from a domain leading peer-reviewed journal.
